Events Archive 2019 2019 - 17 Dec 2019 – APSIC guidelines recommend decolonising S. aureus - 02 Dec 2019 – Destiny Pharma to present at the Partnerships to Tackle the Global Challenge of AMR, UK-China AMR Workshop - 02 Dec 2019 – Directorate Change - Destiny Pharma to present at JPM / Biotech Showcase 2020, 13 – 15 January 2020, San Francisco, USA - Destiny Pharma to attend RSC Novel Strategies for Combatting Antibacterial Resistance event, 9 December 2019, London, UK - Destiny Pharma to attend UK-China AMR Workshop 2019, 3 – 5 December 2019, Beijing, China - 15 Nov 2019 – Destiny Pharma to present at the Inv€$tival Showcase in partnership with Jefferies - Destiny Pharma to present at Emerging Antimicrobials and Diagnostics in AMR 2019 on 19-20 November 2019 in Amsterdam - Destiny Pharma to attend Jefferies 2019 London Healthcare Conference on 20-21 November 2019 in London, UK - 06 Nov 2019 – Destiny Pharma to present at the World Anti‐Microbial Resistance Congress 2019 - 16 Oct 2019 – Positive Phase 1 results published in journal - Destiny Pharma to present at World Anti-Microbial Resistance Congress 2019, 7 – 8 November 2019, Washington DC, USA - Destiny Pharma to present at Life Science IP, 26 – 27 November 2019, London, UK - 24 Sep 2019 – Destiny Pharma Interim results presentation and audio recording - 23 Sep 2019 – Directorate change - 23 Sep 2019 – Interim results for the 6 months ended 30 June 2019 - 11 Sep 2019 – Public Health England announced its new strategy to address AMR - Destiny Pharma to attend BIO-Europe 2019, 11 – 13 November 2019, in Hamburg, Germany - Destiny Pharma to attend CPhI Europe, 5 – 7 November 2019, in Frankfurt, Germany - Destiny Pharma to attend IDWeek 2019, 2 – 6 October 2019, in Washington DC, USA - 10 Sep 2019 – Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections - 02 Sept 2019 – Destiny Pharma XF Drug platform data to be presented at EuroBiofilms - 15 Aug 2019 – Change in Shareholding - 05 Aug 2019 – Destiny Pharma welcomes the US government’s healthcare reform for novel antibacterial drug payments - 31 Jul 2019 – Destiny Pharma to present at the 2019 Gordon Research Conference – 4-9 August 2019 - 17 Jul 2019 – Destiny Pharma to attend Eurobiofilms 2019, 3 – 6 September 2019 in Glasgow, Scotland - 17 Jul 2019 – Destiny Pharma to attend ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, 4 – 6 September 2019 in Boston, USA - 10 Jul 2019 – Development of new antibiotics encouraged with new pharmaceutical payment system - 26 Jun 2019 – Destiny Pharma participated in the UK Global Expert Mission ‘Antimicrobial resistance Germany’ - 04 Jun 2019 – Result of AGM - 05 Jun 2019 – Destiny Pharma to attend OBN BioTuesday on Tuesday 16th July 2019 in Manchester, UK - 20 May 2019 – Destiny Pharma are part of the UK government Global Expert Mission delegation to Germany, 20-24 May 2019 - 09 May 2019 – Pharmafocus publish article “The global rise in antibiotic resistance threatens infection prevention and cure” - 09 May 2019 – Destiny Pharma appoints NOMAD and Joint Broker - 09 May 2019 – Destiny Pharma to present at the US-China Bio-Partnering Forum, 30-31 May 2019, Chicago, USA - 02 May 2019 – Destiny Pharma welcomes United Nations report - 29 Apr 2019 – Posting of Accounts and Notice of AGM - 16 Apr 2019 – Equity Development publish latest research note ‘Destiny Pharma – Bucking the Big Pharma trend’ - 15 Apr 2019 – Destiny Pharma welcomes new BEAM Alliance paper “A new vision for AMR innovation to support medical care” - 11 Apr 2019 – Destiny Pharma 2018 Final Results – finnCap and Edison latest published research – April 2019 - 09 Apr 2019 – Audited Results for the year ended 31 December 2018 - 27 Mar 2019 – Destiny Pharma to attend BioEquity Europe 2019, 20 – 21 May 2019, Barcelona, Spain - 27 Mar 2019 – Destiny Pharma to attend BioTrinity 2019, 30 April – 1 May 2019, London, UK - 27 Mar 2019 – MedPharm to develop new XF-drug formulations - 22 Mar 2019 – Notice of Full Year Results - 19 Mar 2019 – Destiny Pharma to attend European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 13 – 16 April 2019, Amsterdam, Netherlands - 25 Feb 2019 – Edison Investment Research publish Research Note on Destiny Pharma entitled “Prevention is commercially cost effective” - 17 Feb 2019 – Destiny Pharma to attend BIO-Europe Spring, 25 – 27 March 2019, Vienna, Austria - 30 Jan 2019 – Neil Clark, CEO, interviewed at Proactive Investor event on 28 January 2019 - 28 Jan 2019 – Second positive Phase 1 trial data for XF-73 - 25 Jan 2019 – Destiny awarded new UK-China AMR grant - 24 Jan 2019 – Destiny Pharma notes UK 5-year action plan on AMR - 17 Jan 2019 – Destiny Pharma to attend Superbugs & Superdrugs 2019, 18 – 19 March 2019, London, UK - 17 Jan 2019 – Destiny Pharma to attend Novel Antimicrobials and AMR Diagnostics 2019, 14 – 15 March 2019, Berlin, Germany - 17 Jan 2019 – Destiny Pharma to attend UKRI AMR House of Commons Event, 13 February 2019, London, UK Archive 2021 2020 2019
